Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism Read More > June 14, 2003
Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia Read More > February 1, 2003
Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers Read More > June 24, 2002
No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study Read More > February 1, 2001
Role of Serotoninergic Neurons and 5-HT Receptors in the Action of Hallucinogens Read More > January 1, 2000
Ketamine psychedelic therapy (KPT): a review of the results of ten years of research Read More > January 1, 1997
Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis Read More > October 14, 1996
Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Read More > January 1, 1986
Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca Read More > April 1, 1984
Mental changes experimentally produced by d-lysergic acid diethylamide tartrate Read More > January 1, 1952
